However, a recombinant Listeria vaccine expressing a chimeric human HER2/neu construct in a canine osteosarcoma trial showed prolonged overall survival time, with 1-, 2- and 3-year survival rates of 77.8%, 67% and 56% in 18 treated canine patients compared to 55%, 28% and 22% in the historical controls, respectively [87]. This evidence concerns the gene ERBB2 and osteosarcoma.